Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma

J Clin Oncol. 2009 Sep 10;27(26):e97-100. doi: 10.1200/JCO.2009.21.8149. Epub 2009 Jun 29.

Authors

Matthew S Davids¹, Amanda Charlton, Swee-Siang Ng, Mei-Ling Chong, Kevin Laubscher, Mohammed Dar, Jeffrey Hodge, Richie Soong, Boon Cher Goh

Affiliation

¹ Department of Haematology/Oncology, National University Health System, Singapore, Singapore.

PMID: 19564526
DOI: 10.1200/JCO.2009.21.8149

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Base Sequence
Biomarkers / metabolism
Carcinoma, Merkel Cell / drug therapy*
Carcinoma, Merkel Cell / genetics
Carcinoma, Merkel Cell / metabolism
DNA Mutational Analysis
Fatal Outcome
Female
Humans
Indazoles
Keratins / metabolism
Mutation
Neoplasm Metastasis
Phosphopyruvate Hydratase / metabolism
Protein Kinase Inhibitors / therapeutic use
Pyrimidines / therapeutic use*
Receptor, Platelet-Derived Growth Factor alpha / genetics
Scalp
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Skin Neoplasms / metabolism
Sulfonamides / therapeutic use*

Substances

Biomarkers
CAM 5.2 antigen
Indazoles
Protein Kinase Inhibitors
Pyrimidines
Sulfonamides
Keratins
pazopanib
Receptor, Platelet-Derived Growth Factor alpha
Phosphopyruvate Hydratase